Suppr超能文献

用于检测人尿中麦角酸二乙胺(LSD)的非同位素免疫分析方法的开发与验证。

Development and validation of a nonisotopic immunoassay for the detection of LSD in human urine.

作者信息

Cassells N P, Craston D H, Hand C W, Baldwin D

机构信息

Strategic Research Unit, Laboratory of the Government Chemist, Teddington, Middlesex, England.

出版信息

J Anal Toxicol. 1996 Oct;20(6):409-15. doi: 10.1093/jat/20.6.409.

Abstract

A microplate enzyme immunoassay (EIA) for the detection of lysergic acid diethylamide (LSD) in human urine was developed. The assay kit is designed around an LSD derivative coated on the wall of microplate wells with preservatives and stabilizers. Sample and rabbit anti-LSD are added to the microplate well. The immobilized LSD and LSD present in specimens compete for the opportunity to bind to the anti-LSD antibodies. An anti-rabbit antibody labeled with horseradish peroxidase is used to provide the assay signal, which is inversely proportional to the concentration of LSD in the sample. The assay requires a 25-microL urine sample and three consecutive incubation periods of 60, 30, and 30 min at room temperature. The assay was tested with a variety of drugs, including ergot alkaloids spiked into drug-free urine at up to 100,000 ng/mL without cross-reaction. Nor-LSD was shown to cross-react between 16% and 28%, depending on its concentration. Of the other compounds tested, only ergonovine demonstrated slight cross-reactivity at approximately 0.0008%. The assay is designed to be used with a qualitative cutoff of 0.5 ng/mL. Precision testing at 0.5 ng/mL gave a coefficient of variation (CV) of 6% based on 20 replicates. The CV at 0.375 ng/mL (cutoff, -25%) was 5.2% and at 0.625 ng/mL was 6.6%. Precision at other concentrations within the range of the calibration curve gave similar results both intra- and interassay. Clinical performance of the assay was compared with that of a commercial radioimmunoassay (RIA). Comparable performance was observed with both methods, each screening a total of 458 samples as negative and 17 samples as positive relative to a 0.5 ng/mL cutoff. The EIA found an additional three positive samples that were negative by RIA. The EIA is suitable for the screening of urine samples for the presence of LSD. Preliminary indications are that the assay is also suitable for use with whole blood specimens. The assay can be performed manually or be fully automated and without the need for radioactivity; it can be used in any laboratory.

摘要

开发了一种用于检测人尿中麦角酸二乙酰胺(LSD)的微孔板酶免疫测定法(EIA)。该检测试剂盒围绕包被在微孔板孔壁上的LSD衍生物设计,并添加了防腐剂和稳定剂。将样品和兔抗LSD加入微孔板孔中。固定化的LSD与样品中存在的LSD竞争与抗LSD抗体结合的机会。用辣根过氧化物酶标记的抗兔抗体提供检测信号,该信号与样品中LSD的浓度成反比。该检测需要25微升尿液样本,并在室温下连续进行三个60分钟、30分钟和30分钟的孵育期。该检测方法用多种药物进行了测试,包括添加到不含药物尿液中浓度高达100,000纳克/毫升的麦角生物碱,未出现交叉反应。去甲LSD根据其浓度显示出16%至28%的交叉反应。在测试的其他化合物中,只有麦角新碱在约0.0008%时表现出轻微的交叉反应。该检测方法设计的定性临界值为0.5纳克/毫升。在0.5纳克/毫升进行精密度测试,基于20次重复,变异系数(CV)为6%。在0.375纳克/毫升(临界值,-25%)时CV为5.2%,在0.625纳克/毫升时为6.6%。在校准曲线范围内的其他浓度下,批内和批间精密度均得到类似结果。将该检测方法的临床性能与商业放射免疫测定法(RIA)进行了比较。两种方法观察到了可比的性能,相对于0.5纳克/毫升的临界值,每种方法共筛查了458个阴性样本和17个阳性样本。EIA发现了另外3个RIA检测为阴性的阳性样本。EIA适用于筛查尿液样本中是否存在LSD。初步迹象表明该检测方法也适用于全血标本。该检测可以手动进行或完全自动化,且无需放射性;可在任何实验室使用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验